Tag: the war on (some) drugs

Colorado Springs Voters Approve Two Contradictory Marijuana Ballot Measures To Both Allow And Ban Recreational Sales

Colorado Springs voters approved two competing ballot measures this week, one that would ban retail marijuana in the city and another that would allow existing medical marijuana stores to also sell recreationally.

As of 6 p.m. on Wednesday night, about 53 percent of voters approved Ballot Issue 2D, a city charter amendment referred by City Council that would prohibit sales within city limits. About the same share of voters also approved Ballot Question 300, an initiated ordinance which would allow the approximately 90 medical marijuana stores in the city to apply for a recreational license.

Mayor Yemi Mobolade said the result creates “a really interesting legal dilemma for us,” according to Westword.

“Although the election is not final until the results are certified, it appears as though both Ballot Question 2D and Ballot Question 300 will have been approved by the voters. If this is the case, Ballot Question 300 must be read, interpreted, and implemented in a manner to be consistent and harmonious with Ballot Question 2D,” city spokesperson Max D’Onofrio wrote in an email.

The city charter takes precedence over ordinances, so provisions of Ballot Question 300 that conflict with Ballot Issue 2D cannot be implemented, which appears to mean recreational marijuana sales would continue to be outlawed. D’Onofrio said the city is currently reviewing the ballot language. City Council next meets on November 12.

At the same time, backers of Ballot Issue 2D are optimistic.

“When all the votes are counted and the will of voters is given effect, responsible regulation will be law and the city council’s cynical ploy will be defeated,” Citizens for Responsible Marijuana Regulation said in a statement. “We know that those in municipal government will defer to the clearly expressed intent of voters to authorize recreational marijuana, and we look forward to working with city leaders over the coming months to create a responsible regulatory framework.”

Keep reading

‘Outdated’ Marijuana Packaging Rules Make It ‘Impossible’ For Cannabis Industry To Be Environmentally Sustainable, Study Says

A newly published study of product packaging from the commercial marijuana industry concludes that the market shift toward vape pens in recent years has been “a seismic event for cannabis waste,” with packaging from California’s legal market now nearly on par with that of household pharmaceuticals in the state.

But while there’s “a robust infrastructure in place for reverse distribution” of pharmaceuticals, the study notes, “no such infrastructure exists for cannabis waste at large scale.”

The new research, by Oaksterdam University researcher Mitchell Colbert, published this week in the standards organization ATSM International’s Journal of Testing and Evaluation, also highlights how state cannabis regulations contribute to excessive cannabis waste that doesn’t exist for other industries.

The paper describes itself as “a novel attempt to estimate the volume of cannabis consumer packaging waste produced in California each year…and compare it with other household hazardous waste (HHW).”

It notes that while California regulators collected waste data through the state’s track-and-trace program, that information “is not publicly available even with a state Public Records Act request to the [Department of Cannabis Control].” Instead the study looked at a sample of cannabis packaging of 256 California cannabis products from 138 manufacturers, combining those findings with sales data on the number of product units sold.

Keep reading

RFK Jr. Declares War on Big Pharma: Vows to Clear Out ‘Entire Departments’ at the FDA in Push for Health Reform

Robert F. Kennedy Jr., known for his relentless stance against corporate influence in health policy, is now taking direct aim at the entrenched bureaucracies within the U.S. health agencies.

As a possible future Trump administration appointee, RFK Jr. has laid out a plan to rid the FDA and other key federal agencies of the deeply-rooted corruption that prioritizes corporate profits over public health.

Recall that Trump said that if he is elected, Kennedy will work on “health and women’s health ” and the nation’s food supply.

“Robert F. Kennedy Jr. we have. And he’s going to work on health and women’s health and all of the different reasons, because we’re not really a wealthy or a healthy country,” Trump said during his rally in Nevada.

“I told Bobby, ‘I want you to take care of health, I want you to look at the food and the food supply and what we put on the food and all sorts of — you can look at, but let me handle the oil and gas, Bobby,’” Trump added.

In Kennedy’s crosshairs are not only the FDA but also the Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the Department of Agriculture (USDA).

On Saturday, Robert Kennedy Jr. announced that the Trump administration would advise all U.S. water systems to remove fluoride from tap water on day one.

“On January 20, the Trump White House will advise all U.S​. water systems to remove fluoride from public water,” Kennedy wrote. “Fluoride is an industrial waste associated with arthritis, bone fractures, bone cancer, IQ loss, neurodevelopmental disorders, and thyroid disease. President ​Donald Trump and First Lady Melania Trump want to Make America Healthy Again.”

Keep reading

Trump’s top healthcare priority must be repealing Big Pharma’s legal immunity for vaccines

Lawsuits aren’t fun.

At best they’re draining and distracting – especially against big companies with tough legal teams. (Trust me.) Federal courts have now raised the bar even to reach the “discovery” phase of suits, where plaintiffs can see documents relevant to their claims.

No, lawsuits aren’t fun. No one sues a Fortune 500 company for kicks.

But sometimes they’re are necessary. Except, apparently, when it comes to vaccines1.

In its infinite wisdom, in 1986, Congress passed a law making it nearly impossible for any American to sue pharmaceutical companies over vaccine injuries. Instead, it routed all claims to a special federal court program that would judge possible injuries on a “no-fault” basis and compare them to a prespecified list of injuries.

Keep reading

Vaccines Contain Glyphosate, One of the Most Toxic Chemicals on the Planet

Childhood vaccines were originally developed to protect young children from virulent, sometimes lethal, diseases.

According to mainstream medicine, “Vaccines have played a crucial role in reducing the burden of infectious diseases.”

“A May study in the Lancet estimated that vaccines against 14 common pathogens have saved 154 million lives over the past five decades—at a rate of six lives every minute,” asserts Tara Haelle in a Scientific American article published this week called “The Staggering Success of Vaccines.”

At the same time, even the most diehard vaccine supporters found themselves ill at ease during COVID when they learned that unvaccinated children were being barred from public life and vaccine-hesitant people had to be bribed to take the COVID-19 vaccine.

Keep reading

FDA Knows That China and India Drug Quality Is Poor, But Independently Collects and Tests Only about 0.001%

Quality control errors during pharmaceutical manufacturing are unfortunately common occurrences. The majority (around 50%) of employees that work in pharmaceutical manufacturing tend to have duties which are safety/quality-control related, but apparently even that isn’t enough. 

Even with a major focus on quality, there is still an estimated 2-3σ (sigma) level of imprecision when it comes to pharmaceutical manufacturing. That corresponds to 66,807 to 308,537 defects per 1,000,000 opportunities. But with pharmaceutical development being so complicated, there could be more than 1,000,000 “opportunities” for error. 

The above listed error calculation – while alarming enough – was referenced in small-molecule pharmacology. However, increasingly complex pharmaceuticals (such as today’s widely used biotechnological products, including GLP-1 diabetes/weight loss or mRNA products for Covid-19) have molecular weights that can be thousands times larger than small molecule compounds. That could mean an even greater opportunity for error. 

The FDA is abundantly aware of pharmaceutical fragility and potential quality shortcomings, including at the highest levels of its leadership. 

In fact, Dr. Michael Kopcha, the current Director of the FDA’s Office of Pharmaceutical Quality (OPQ), wrote and published the above published Six Sigma calculation, lamenting the imprecise nature of pharmaceutical manufacturing – back in 2017. 

Any alteration in structure that occurs during manufacturing has the potential to vastly change a compound’s clinical activity, including a change from therapeutic drug into a poison.

Keep reading

Kamala Claims She Will Legalize Recreational Marijuana in Last-Ditch Vote Pandering Scheme After JAILING People for Pot Possession

Kamala Harris took to social media on Sunday, just days before Election Day, with a claim that she will legalize recreational marijuana. Unfortunately for the Democrat presidential hopeful, she made her career on locking up individuals who were in possession of small amounts of weed.

“I will legalize recreational marijuana, break down unjust legal barriers, and create opportunities for all Americans to succeed in this new industry,” Harris said in a social media post on Sunday.

1,560 people were sent to state prison for marijuana-related offenses in California under then-state attorney general Harris.

“Under Harris’s six-year tenure, hundreds were sent to state prisons for marijuana-related offenses, crime records show,” The Washington Free Beacon said in 2019.

On a debate stage in Detroit, Michigan in 2019, Tulsi Gabbard, then a Hawaii representative and rival for the Democratic nomination lambasted Harris over her anti-pot record.

Keep reading

DEA Marijuana Rescheduling Hearing Delayed Until 2025, Agency Judge Rules

The Drug Enforcement Administration’s (DEA) hearing on the Biden administration’s marijuana rescheduling proposal is being delayed until 2025, Marijuana Moment has learned.

After DEA Administrator Anne Millgram signed off on over two dozen witnesses to participate in the hearing on Monday, Chief Administrative Law Judge (ALJ) John Mulrooney issued a preliminary order on Thursday signaling that the information provided on those set to testify was insufficient and requesting additional details and potential availability for a formal hearing in January or February 2025.

When the Justice Department proposed moving cannabis from Schedule I to Schedule III in March following a scientific review, advocates and stakeholders had hoped the rule would be finalized this year. And DEA did schedule the hearing for December 2—after the presidential election but before the January inauguration that will see an administrative changeup.

Now the latest order from Mulrooney clarifies that won’t be the case.

The reason being is that DEA’s list of hearing participants who were selected and sent to the ALJ’s office provided “no indication in the four corners of the document as to whether the ‘participants’ support or oppose the [notice of proposed rulemaking] or how the ‘participants’ satisfy the ‘interested person’ definition set forth in the regulations,” the judge’s order says.

“Indeed, the [Participant Letter] contains only a list of persons and organizations accompanied by one or more email addresses, without the benefit of notices of appearance, addresses, or even phone numbers,” it says.

The order from the DEA ALJ says that selected participants must provide such details by November 12. DEA is mandated to provide “its counsel(s) of record who will be appearing in these proceedings, as well as any known conflicts of interest that may require disclosure” on the same date.

Keep reading

JD Vance Asks Joe Rogan For Advice On Providing Psychedelics Access To Veterans After Being ‘Fascinated’ By Drug War History Lesson

Sen. JD Vance (R-OH), former President Donald Trump’s vice presidential running mate, says he’s “fascinated” by the therapeutic potential of psychedelics, asking podcaster Joe Rogan for advice on a creating a possible “pathway” for providing access to substances such as MDMA and psilocybin for military veterans with serious mental health conditions.

Vance told Rogan that his overall philosophy on marijuana and psychedelics is “live and let live,” and he reaffirmed that he feels people should not be criminalized over cannabis. The podcast host also gave the senator a history lesson on marijuana prohibition that Vance said he had “no idea” about.

While the candidate has previously discussed his position that states should have the right to set their own cannabis policies, this is the first time he’s publicly weighed in on laws around psychedelics, though he made clear he’s “not committing to some public policy” and needs to “be careful with this stuff, especially six days from an election.”

After Rogan described research on the medical value of psychedelics and the lack of access to such substances under the current federal drug scheduling statute—as well as the racially discriminatory history of marijuana prohibition—Vance said he “had never heard about” those particular points.

“I’m a veteran too. I spent four years in the Marine Corps—went to Iraq, went to Haiti once,” he said. “What is the pathway, I guess? Or what do you think should happen for veterans accessing psychedelics?”

Rogan told the senator “there are so many anecdotal stories about veterans experiencing relief that I think it should be available to them, especially veterans.”

Vance followed up, inquiring about whether psychedelics access would be incumbent on approval by the Food and Drug Administration (FDA).

“If it had a medical use, presumably, you would get it off of Schedule I [of the Controlled Substances Act (CSA)]. So why aren’t we—I’m just fascinated by this. This is the first time I’ve heard about this,” the senator said.

Keep reading

NYC law used to shutter unlicensed weed bodegas is unconstitutional, judge rules

A Queens judge ruled Tuesday that the local law that let New York City rapidly shut down more than 1,000 businesses accused of selling cannabis without licenses is unconstitutional because it denies shop owners their rights to due process.

The decision calls the legality of the closures into question and has the potential to halt the city’s enforcement effort, known as Operation Padlock to Protect, which Mayor Eric Adams has repeatedly hailed as a success.

Liz Garcia, a spokesperson for the mayor, said Tuesday the city will appeal the ruling.

“Illegal smoke shops and their dangerous products endanger young New Yorkers and our quality of life, and we continue to padlock illicit storefronts and protect communities from the health and safety dangers posed by illegal operators,” she said.

The city updated its administrative code earlier this year to make it easier to shut down stores suspected of selling cannabis without licenses. But New York Supreme Court Justice Kevin Kerrigan has ruled that the portions of the city’s law that allow the sheriff to unilaterally decide whether to keep a store closed for up to a year are unconstitutional.

Under the law, the owner of a business that has been padlocked for allegedly selling cannabis without a license is entitled to a hearing with the Office of Administrative Trials and Hearings, or OATH. After listening to the facts of the case, the hearing officer makes a recommendation as to whether the store should remain closed.

But the ultimate decision is up to the sheriff — and lawyers representing businesses that have been shut down say it’s not uncommon for the sheriff to ignore OATH’s recommendations.

Keep reading